| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 732 | 409 | 27 |
| Full Text Views | 21 | 4 | 1 |
| PDF Downloads | 26 | 6 | 1 |
Radical Cure of Chesson Strain Vivax Malaria in Man by 7, Not 14, Days of Treatment with Primaquine
David F. Clyde
David F. Clyde
University of Maryland School of Medicine, Baltimore, Maryland 21201
Search for other papers by David F. Clyde in
Current site
Google Scholar
PubMed
Search for other papers by David F. Clyde in
Current site
Google Scholar
PubMed
Vincent C. McCarthy
Vincent C. McCarthy
University of Maryland School of Medicine, Baltimore, Maryland 21201
Search for other papers by Vincent C. McCarthy in
Current site
Google Scholar
PubMed
Search for other papers by Vincent C. McCarthy in
Current site
Google Scholar
PubMed
Glucose-6-phosphate dehydrogenase-normal adult volunteers infected with mosquito-borne Chesson strain vivax malaria were treated with chloroquine and primaquine during the initial attack. Administration of 60 mg (base) of primaquine daily for 7 days was as effective in preventing relapse as is the regimen customarily used for the radical cure of infections produced by this strain, namely, 30 mg daily for 14 days. However, it is stressed that because of the risk of primaquine-induced hemolysis in individuals having genetically-transmitted erythrocyte abnormalities this high dosage should not be used routinely.
Author Notes
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 732 | 409 | 27 |
| Full Text Views | 21 | 4 | 1 |
| PDF Downloads | 26 | 6 | 1 |